23P Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial von Veelen, A.V.

Volltext

48P Efficacy of osimertinib (osi) on (prevention of) bone metastases (mets) and skeletal related events (SREs) in patients (pts) with epidermal growth factor receptor mutated (EGFR... von Brouns, A., Veelen, A.V., Veerman, M., Steendam, C., Dursun, S., Croes, S., Dingemans, A-M.C., Hendriks, L.

Volltext

1130P Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR+) non-small cell lung cancer (NSCLC) patients (pts), with a focus... von Veelen, A.V., Veerman, M.G.D., Verschueren, M., Gulikers, J., Brouns, A., Dursun, S., Mathijssen, R.H., Dingemans, A-M.C., Tjan-Heijnen, V.C.G., Peters, B., Souverein, P., Driessen, A., Hendriks, L., van Geel, R., Croes, S.

Volltext